3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder

Tuesday July 23rd, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor. The incorporation of this new main shareholder comes after INFARCO, […]